Home / Business and Economy / Chai Discovery Raises $400M for AI Drug Design
Chai Discovery Raises $400M for AI Drug Design
14 Jul
Summary
- Chai Discovery secured $400 million in funding.
- The company is now valued at $3.8 billion.
- AI is increasingly used for drug discovery and design.
Chai Discovery announced on Tuesday that it has secured $400 million in new funding, a development that now values the company at $3.8 billion.
This significant investment round was spearheaded by Index Ventures, with participation from Kleiner Perkins, Sequoia Capital, and Dimension. Other notable contributors included Bain Capital Ventures, Thrive Capital, OpenAI, and Yosemite.
The substantial funding influx underscores a growing investor confidence in artificial intelligence applications specifically tailored for the life sciences sector. This trend sees capital flowing into specialized AI tools aimed at pioneering new drug development, differentiating from the focus on broader AI models.
Chai Discovery is not alone in this burgeoning field. Isomorphic Labs, a spin-off from Google, has also attracted considerable venture capital, raising $2.7 billion since March 2025. This suggests a broader industry-wide embrace of AI's potential to revolutionize drug discovery.
